Navigation Links
Protein test detects early-stage, asbestos-related pulmonary cancer
Date:4/4/2011

ORLANDO, Fla. Researchers investigating a novel biomarker test believe it is the most accurate yet in detecting proteins secreted from tumors caused by exposure to asbestos. Study results of this aptamer proteomic technology were presented at the AACR 102nd Annual Meeting 2011, held April 2-6.

In a blinded test performed under the auspices of the National Cancer Institute's Early Detection Research Network Biomarker Discovery Lab, the proteomic assay could detect 15 of 19 cases of malignant pleural mesothelioma that were in stage 1 or stage 2, making the test about 80 percent sensitive, a measure of how accurately a test can identify disease. In addition, the specificity of the test was 100 percent, meaning there were no false positives in this study.

Harvey I. Pass, M.D., director of the division of thoracic surgery and thoracic oncology at NYU Langone Medical Center and the NYU Cancer Institute in New York, and colleagues used the SomaLogic, Inc. aptamer proteomics platform to examine 170 blood samples from 90 patients diagnosed with malignant mesothelioma and 80 participants who had been exposed to asbestos. Three-fourths of the samples were used to derive 19 significant biomarkers for mesothelioma and the remaining 25 percent were used in the blinded test.

Malignant pleural mesothelioma is an aggressive, asbestos-related pulmonary cancer that is increasing in incidence. Experts believe this form of cancer will not peak for another 20 years due to a latency period of 20 to 40 years from asbestos exposure. It currently causes an estimated 15,000 to 20,000 deaths per year worldwide. Once diagnosed, the disease is usually fatal (within 14 months) because of the advanced stage that it is typically found. The goal of a diagnostic test such as this one is to find the cancer early enough to effectively treat it, according to Pass.

"The only patients that seem to benefit from therapy in mesothelioma are those that are found in stage 1, and this is only 10 to 15 percent of patients," he said. "Moreover, when found early, the magnitude of the operation necessary to reduce the burden of disease may be less, making the patient better able to cope if the disease recurs and the patient needs more aggressive therapy."

The research team tested the assay produced by SomaLogic, Inc. Its "Multiplex SOMAmer Assay" currently measures more than 1,000 proteins simultaneously from a sample of blood as small as 0.003 of a teaspoon, and can handle 300 samples a day, according to Pass. The assay uses SOMAmers chemically modified single-stranded DNA molecules that fold into different structures and bind specifically to target proteins to identify and quantify proteins across a broad range of concentrations.

According to Pass, this platform combines the best qualities of an immunoassay, and is able to find and quantify low abundance proteins secreted by tumor cells. Ongoing studies are refining the test and validating the results in other patient blood samples, according to Pass.


'/>"/>

Contact: Jeremy Moore
Jeremy.Moore@aacr.org
267-646-0557
American Association for Cancer Research
Source:Eurekalert

Related medicine news :

1. New and Delicious, Almond Butter Filled, Cookie Bites With 35.7% Protein to Help Manage Weight and Build Muscle
2. Research highlights role of protein pair in obesity regulation
3. Urine protein test might help diagnose kidney damage from lupus, UT Southwestern researchers find
4. Smithfield, United Food and Commercial Workers Union, and Food Networks Paula Deen to Deliver 150,000 Servings of Protein to San Francisco Food Bank
5. Protein Sciences Corporation Announces Profitable and Cash Flow Positive Results for 2009 and Management Realignment
6. Protein Appears Key to Intestinal Balance
7. SIBLING proteins may predict oral cancer
8. Damaged protein identified as early diagnostic biomarker for Alzheimers disease in healthy adults
9. Cells of aggressive leukemia hijack normal protein to grow
10. Omega Protein Comments on California Lawsuit Alleging Fish Oil Contaminants
11. Proteins May Predict Spread of Colon Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/10/2016)... ... February 09, 2016 , ... A new leadership team for Mid-South ... President Joe Wiley made the announcement Monday night, Feb. 8, prior to the evening ... of FHU and the creator of GO! Camp, has been named director. Gayle McDonald, ...
(Date:2/10/2016)... (PRWEB) , ... February 09, 2016 , ... ... at Clevens Face and Body Specialists are delighted to welcome a new addition ... joins Clevens Face and Body Specialists as a nurse practitioner performing cosmetic ...
(Date:2/10/2016)... ... February 09, 2016 , ... Traumatic ... cause of injury may be one of many possible sources: sports, car accidents, ... Education Course , Mastering Rehab Solutions for the Complexities of Concussions ...
(Date:2/9/2016)... Florida (PRWEB) , ... February 09, 2016 , ... Steven ... the Taste of South Florida Event, an upscale fundraiser held in South Florida. The ... sponsors and guests alike. This year the event will be held in a new, ...
(Date:2/9/2016)... ... February 09, 2016 , ... Interstate Restoration LLC, a full ... today the acquisition of Hawaii DKI. Hawaii DKI is one of the more ... companies who excel at service and response helps support our goal of becoming ...
Breaking Medicine News(10 mins):
(Date:2/9/2016)... Blood Monitoring & Cardiac Monitoring Devices Market Assessment & Forecast: 2015-2019" ... market for blood monitoring & cardiac monitoring devices was valued at ... 24,830.1 million by 2019 at a CAGR of 6.8% from 2015 ... Europe , Asia-Pacific , Latin ... Africa . The three major factors determining growth of the ...
(Date:2/9/2016)... , Feb. 9, 2016  Increasingly, health care ... their vital signs with wireless technology. With the Vios ... automate patient oversight and remotely detect problems before they ... signs across in-hospital environments. the United ... United States . --> The ...
(Date:2/9/2016)... , Feb. 9, 2016  Johnson & Johnson (NYSE: ... Markets Global Healthcare Conference on Tuesday, Feb. 23, at ... Dominic Caruso , Vice President, Finance & Chief Financial ... will represent the Company in a session scheduled at ... --> www.investor.jnj.com . --> This ...
Breaking Medicine Technology: